The global market for oral proteins and peptides is projected to reach USD 24.00 billion by 2030 from USD 8.85 billion in 2025, at a CAGR of 22.1% during the forecast period from 2025 to 2030.
Scope of the Report
Years Considered for the Study
2024-2030
Base Year
2024
Forecast Period
2024-2030
Units Considered
Value (USD billion)
Segments
Molecule, Drug Class, Therapeutic Area, Formulation, and End User
Regions covered
North America, Europe, Asia Pacific, Latin America, Middle East, and Africa
The increase in demand for oral peptides, particularly for the treatment of chronic diseases such as diabetes and central nervous system (CNS) disorders, is a major driver of growth in this market. Additionally, rising investments in research and development by key players are leading to the creation and launch of innovative oral peptides. Continuous advancements in drug delivery technologies are also contributing to market expansion.
However, the market faces challenges, including high development costs and obstacles related to formulation and stability, which hinder growth.
"The semaglutide molecule segment accounted for the largest share of the market, by molecule, in 2024."
In 2024, the semaglutide segment held the largest share of the global oral proteins and peptides market. Semaglutide is an analog of glucagon-like peptide-1 (GLP-1), a hormone that plays a key role in regulating blood sugar levels and appetite. It is used to manage type 2 diabetes and obesity. Semaglutide functions by enhancing insulin secretion in response to elevated blood glucose levels, reducing glucagon release (which normally raises blood sugar), and promoting a feeling of fullness after eating, thereby helping to reduce food intake.
Oral semaglutide, marketed as RYBELSUS, is the first oral GLP-1 receptor agonist approved by the US FDA for the treatment of type 2 diabetes. As a class, GLP-1 receptor agonists are widely utilized and recommended for managing type 2 diabetes.
"The US will continue to dominate the oral proteins and peptides market during the forecast period."
The US is the largest biopharmaceutical market in the world and a leader in biopharmaceutical research and investments. This growth is driven by several factors, including the increasing patient population suffering from infectious diseases, the rising importance of biopharmaceuticals, and the need for safe, high-quality products in the healthcare sector. There has been a significant increase in investments and funding for biomedical research from government agencies as well as pharmaceutical and biotechnology companies.
Furthermore, the early adoption of emerging technologies and alternative therapies and the widespread availability of oral proteins and peptides in the region support market expansion. The strong presence of several key market players, including Novo Nordisk A/S (Denmark), AbbVie, Inc. (US), and Pfizer Inc. (US), is another crucial factor contributing to this growth.
The primary interviews conducted for this report can be categorized as follows:
By Respondent: Supply Side (70%) and Demand Side (30%)
By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%)
By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and Middle East & Africa (5%)
List of Key Companies Profiled in the Report:
Novo Nordisk A/S (Denmark), AbbVie Inc. (US), Pfizer Inc. (US), Acadia Pharmaceuticals Inc. (US), Aurinia Pharmaceuticals Inc. (Canada), Bausch Health Companies Inc. (Canada), CHIESI Farmaceutici S.p.A. (Italy), EnteraBio Ltd. (Israel), Merck & Co., Inc. (US), Johnson & Johnson Services, Inc. (US), R-Pharm JSC (Russia), Proxima Concepts (US), and SWK Holdings Corporation (US)
Research Coverage:
This research report categorizes the oral proteins and peptides market by molecule (trofinetide, semaglutide, linaclotide, voclosporin, plecanatide, calcitonin, and other drugs), drug class (analog of glycine-proline-glutamate (GPE), glucagon-like peptide-1 (GLP-1) receptor agonists, guanylate cyclase-C agonists, calcineurin-inhibitor immunosuppressants, calcitonin gene-related peptide (CGRP) receptor antagonists, and other drugs), therapeutic area (genetic disorders, diabetes, nephrology, gastroenterology, CNS disorders, obesity & overweight, and other therapeutic areas), formulation (tablets, capsules, and oral solutions), end user (home care settings, long-term care facilities, and hospitals & specialty clinics), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the oral proteins and peptides market. A comprehensive analysis of key industry players has been conducted to provide insights into their business overview, products, solutions, strategies, collaborations, partnerships, agreements, new launches, acquisitions, and recent developments associated with the oral proteins and peptides market.
Key Benefits of Buying the Report:
The report will help market leaders and new entrants by providing the closest approximations of the revenue numbers for the oral proteins and peptides market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
Analysis of key drivers (rising prevalence of chronic diseases such as diabetes, gastroenterology diseases, and kidney diseases; advancements in drug delivery technologies; patient preference and compliance for oral route of drug administration; and increasing adoption of inorganic growth strategies such as collaborations and agreements), restraints (high cost associated with drug development, contraindication of oral proteins and peptides, and stringent regulatory approval process), opportunities (robust clinical trial pipeline for oral proteins and peptides and growing demand for non-invasive and patient-friendly treatment options), and Challenges (hurdles in formulation and stability and availability of alternative therapies) influencing the growth of the market.
Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the oral proteins and peptides market.
Market Development: Comprehensive information about lucrative markets; the report analyzes the market across varied regions.
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the oral proteins and peptides market.
Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the oral proteins and peptides market.
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS AND REGIONS COVERED
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 RESEARCH DESIGN
2.1.2 SECONDARY DATA
2.1.3 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION
2.2.1 INSIGHTS FROM PRIMARIES
2.2.2 MARKET SIZE ASSESSMENT AT SEGMENT LEVEL
2.3 MARKET GROWTH FORECAST
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
2.5 STUDY ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 ORAL PROTEINS & PEPTIDES MARKET OVERVIEW
4.2 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET SHARE, BY FORMULATION AND COUNTRY (2024)